Onconova Therapeutics (ONTX) Phase 2 Oral Rigosertib and Azacitidine Data at ASH Shows 35% Complete Remission Rate
Tweet Send to a Friend
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced the presentation of data from a Phase 2 clinical trial of oral rigosertib and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
